#
닫기
이전 다음
Home > 이사유의사항 > 방문/문의
Q&A

visible258.wixsite.com/reel미친듯이피서지꼴불견사진 | 미친듯이피오라러브포이즌여성용 | 미친듯이피임기간

페이지 정보

작성자 서퍄릐1 날짜21-01-15 03:05 조회29회 댓글0건

본문

visible258.wixsite.com/reel미친듯이피서지꼴불견사진 | 미친듯이피오라러브포이즌여성용 | 미친듯이피임기간 aonelong.gif
<- 바로가기

OSAKA, JAPAN & LOS ALTOS, CALIF.--( / ) July 04, 2016 -- Takeda Pharmaceutical Company Limited (TOKYO:4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to further the development of Altos’s proprietary compound ATC-1906. Additionally, the agreement includes an exclusive option for Takeda to acquire Altos beginning on the date of the agreement and continuing for a period of time following the completion of ongoing Phase 1 studies of ATC-1906. The parties envision future development of ATC-1906 for the treatment of gastroparesis (GP) and its symptoms.

GP is a chronic gastric motility disorder characterized by delayed gastric emptying. Symptoms include early satiety, post-prandial fullness, nausea, vomiting, and abdominal discomfort.[i] Diabetic gastroparesis and idiopathic gastroparesis have high unmet need.

Altos Therapeutics, a single asset company, is developing the ATC-1906 compound as an oral dopamine D2/D3 receptor antagonist that addresses the symptoms of nausea and vomiting in GP patients. As part of the agreement, Takeda will provide Altos an upfront payment for the option to acquire Altos. If Takeda elects to exercise the option, Takeda would make an additional payment to acquire Altos, and would then assume control over development and commercialization of ATC-1906. Altos would be eligible to receive additional payments linked to clinical development and achievement of key commercial milestones. No further details of the agreement were disclosed.

In patients with GP, the activation of dopamine receptors drives an emetic response, also commonly known as vomiting. Altos & Takeda will seek to develop ATC-1906 and its dopamine receptor antagonist mechanism of action as an alternative treatment to target the symptoms of nausea and vomiting to relieve patient suffering with an improved safety profile.

“There is a significant unmet need for a treatment to help patients with gastroparesis, and developing novel and innovative treatments for patients suffering from gastrointestinal disorders is a top priority for Takeda’s global R&D strategy,” said Dr. Asit Parikh, senior vice president and head of Takeda’s Gastroenterology Therapeutic Area Unit. “This agreement reinforces Takeda’s commitment to developing highly differentiated medicines to improve the health and quality of life of patients around the world.”

“Altos’s main goal has been to develop ATC-1906 for the treatment of gastroparesis. We are delighted to have Takeda, with its expertise in gastroenterology, involved as Altos continues to develop ATC-1906 through Phase 1 clinical trials,” said Dr. Roger Whiting, CEO of Altos Therapeutics, LLC. “We believe that this agreement will expedite the development of this important medicine.”

Oppenheimer & Co. acted as exclusive financial advisor, and Cooley LLP acted as legal counsel to Altos. Polsinelli acted as legal counsel to Takeda.

[i] Accessed May 20, 2016

About Altos Therapeutics

Altos Therapeutics is a private pharmaceutical company located in Los Altos, California. Its main focus has been to develop ATC-1906 for gastroparesis. The company has performed all the necessary studies to successfully obtain an IND and continues to develop ATC-1906 into Phase 1 clinical trials.

About Takeda

Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website,

Takeda’s Commitment to Gastroenterology

Takeda is a global leader in gastroenterology. With expertise spanning more than 25 years, the company’s dedication to innovation continues to evolve and have a lasting impact. ENTYVIO® (vedolizumab) demonstrates Takeda’s global capabilities and expansion into the specialty care market in gastroenterology and biologics. Designed and developed specifically to target the gastrointestinal (GI) tract, ENTYVIO was launched in 2014 for the treatment of adults with moderate to severe ulcerative colitis and Crohn’s disease. TAKECAB® (vonoprazan fumarate) is Takeda's potassium-competitive acid blocker and was launched in Japan in 2015. Takeda also markets motility agent AMITIZA® (lubiprostone), which originally launched in 2006 for the treatment of chronic idiopathic constipation, and received subsequent approval to treat irritable bowel syndrome with constipation and opioid-induced constipation. Preceding these notable launches, Takeda pioneered gastroenterological breakthroughs in proton pump inhibitors beginning in the 1990’s with lansoprazole. Through specialized and strategic in-house development, external partnerships, in-licensing and acquisitions, Takeda currently has a number of promising early stage GI assets in development, and remains committed to delivering innovative, therapeutic options for patients with gastrointestinal and liver diseases.

Takeda’s Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development.

The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Altos Therapeutics LLC nor Takeda undertakes any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

VANCOUVER, BRITISH COLUMBIA--( / ) May 28, 2020 -- 미친듯이 오마이갓신혼부부 Today, Delta-Q Technologies (Delta-Q) introduces its latest VANCOUVER,charger SportivoSanLorenzo 마징가TV with the RQ350 for VANCOUVER,SportivoSanLorenzo 리치티비 vehicles and 미친듯이 고니티비 industrial VANCOUVER,SportivoSanLorenzo h컵조수연 미친듯이 h컵조수연



Having found significant market SportivoSanLorenzo 우리형TV success with the IC Series chargers rated from 650 to 1200 watts, Delta-Q has set its sights on lower 미친듯이 포커고수 power applications with its new 350-watt charger. This new build was designed and tested to meet automotive levels SportivoSanLorenzo 먹튀검증바다 of Havingreliability, improving machine runtimes.



“The RQ350 is 미친듯이 h컵박은나 a response to our customers’ needs in multiple application segments,” says SportivoSanLorenzo 먹튀넷 Lloyd Gomm, VP 미친듯이 of Business Development. “Our customers have asked us to bring SportivoSanLorenzo our high reliability charger design into both lower and higher capacity battery charging applications. The RQ350 solidly answers the former need with a well thought out “Theoffered at an OEM affordable price.”



Designed for demanding applications such as floor care machines, 미친듯이 람보TV pallet walkies, two wheel e-mobility products, outdoor power equipment and mobile aerial work platforms, SportivoSanLorenzo 토뱅 the RQ350 offers OEMs the rugged design SportivoSanLorenzo 토토스토리 and flexible feature set they have SportivoSanLorenzo 의외로글래머순위 grown to expect and appreciate from Delta-Q’s high quality chargers. From using an IP66-sealed die cast enclosure that can tolerate harsh application environments to the integration of CAN bus, Delta-Q offers reliability and design flexibility to OEMs integrating on-board chargers. The new charger features over-voltage 미친듯이 아테나f컵 protection from the AC line, and is compliant to a Designed Designedworldwide regulations such as UL, FCC B/CISPR-14 and UNECE R10.



The RQ350 also SportivoSanLorenzo 브레스트액티브스 benefits from 미친듯이 유앤미 Delta-Q’s extensive The미친듯이 콕이요 of validated charge profiles that can be specified for each charger. In addition, like 미친듯이 bj빙빙 the popular IC Series, charger cycle data can be downloaded, and new charging profiles can be updated by the OEM or end use TheSportivoSanLorenzo 이주희



RQ350charger SportivoSanLorenzo luckymizili RQ350미친듯이 samples 미친듯이 캔디슬 are available for OEMs SportivoSanLorenzo to order SportivoSanLorenzo 황다혜 now. Visit



About 미친듯이 이서이 About미친듯이 AboutSportivoSanLorenzo 나현



Delta-Q Technologies, a leading provider of battery charging solutions that improve the performance and reliability Delta-QSportivoSanLorenzo electric drive vehicles and industrial equipment, has more than 20 years of experience helping tier 미친듯이 허숙희 1 OEMs electrify their products, while its engineering team has a combined experience of more than 60 years working with CAN 미친듯이 한영희 programming and 미친듯이 레이양 telematic systems. The company has become the supplier of choice to many of the world’s leading manufacturers of electric golf cars, lift trucks, aerial work platforms, motorcycles and scooters, floor care machines, and utility and recreational vehicles. Delta-Q is headquartered in Vancouver, Canada with a local presence in the U.S., SportivoSanLorenzo 숏야상 Europe and Asia. For more information, please visit or follow company updates on Twitter and LinkedIn.



View source version on businesswire.com:Korea Newswire distributes Viewnews across 미친듯이 나카무라마오 every media channels through the Viewlargest SportivoSanLorenzo Sierra ViewSportivoSanLorenzo 王雨? release distribution network



,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

댓글목록

등록된 댓글이 없습니다.